Physician profile
Cameron S Griffith
NPI 1518097815
$7,174.97
in general payments reported to CMS, 2019-2025
22 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $1,435 · 2021: $1,136 · 2022: $622 · 2023: $482 · 2024: $796 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.41 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,487.01 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Glaukos Corporation | $1,312.54 | 2020-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Idose |
| Abbvie INC. | $705.85 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $423.47 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $402.43 | 2020-2025 | Tecnis Simplicity, Tecnis Iol |
| Allergan, INC. | $392.82 | 2020-2021 | |
| Staar Surgical Company | $253.30 | 2019 | |
| Rxsight INC | $208.24 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| New World Medical,INC. | $179.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $179.34 | 2019-2021 | |
| Beaver-Visitec International, INC. | $149.26 | 2020-2023 | |
| Dompe US, INC. | $98.68 | 2024-2025 | Oxervate |
| Ivantis, INC | $76.12 | 2020-2021 | |
| Sight Sciences, INC. | $69.33 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $55.07 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $52.72 | 2025 | |
| Carl Zeiss Meditec, INC. | $50.02 | 2019 | |
| Oyster Point Pharma, INC. | $21.02 | 2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $18.37 | 2025 | Dextenza |
| Bausch & Lomb Americas INC. | $14.53 | 2024 | Vyzulta, Miebo |
| Shire North American Group INC | $12.69 | 2019 | |
| Omeros Corporation | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.